IP Library › Granted Patent US 7,326,411
Granted Patent B2
US 7,326,411 · App. 11/072,454 · Granted Feb 5, 2008

Use of amino-terminally truncated RANTES to inhibit HIV viral replication

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,326,411
App. No.
11/072,454
Granted
Feb 5, 2008
Kind
B2
Abstract

The present invention relates to amino-terminally truncated RANTES, lacking NH 2 -terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.

Claims (1)

1. A method for inhibiting HIV replication comprising contacting HIV infected cells with an effective amount of an amino terminally truncated RANTES polypeptide consisting of residues 3-68 of a RANTES polypeptide according to SEQ ID NO:1.

Assignments (2)
CHANGE OF NAME Recorded Nov 25, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023569/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →